Home > Insider Trading > Filing (0001562180-16-001766)

Filing Details

Accession Number:: 0001562180-16-001766
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-02-23 17:48:26
Reporting Period:: 2016-02-19

Filing Date:: 2016-02-23
Accepted Time:: 2016-02-23 17:48:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1515673	Ultragenyx Pharmaceutical Inc.	RARE	Pharmaceutical Preparations (2834)	272546083

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1616640	Sunil Agarwal	C/O Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato CA 94949	Chief Medical Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-02-19	384	$63.27	11,308	No	4	F	Direct
Common Stock	Disposition	2016-02-22	658	$63.48	10,650	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	F	Direct
No	4	S	Direct

Footnotes

Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due upon vesting of Restricted Stock Units granted to the Reporting Person under the Issuers 2014 Incentive Plan. The shares surrendered were valued based on the closing price of the Issuers common stock on the vesting date.
Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
This amount reflects a corrected balance due to clerical error. The number of shares as beneficially owned reported in December 2015 and January 2016 were 498 shares too high. The Form 4 filed on December 22, 2015 should have reported 13,231 shares as beneficially owned instead of 13,729 shares; the Form 4 filed on December 24, 2015 should have reported 12,733 shares as beneficially owned instead of 13,231 shares; and the Form 4 filed on January 21, 2016 should have reported 11,692 shares as beneficially owned instead of 12,190 shares.
The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.40 to $63.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.